Literature DB >> 25989253

Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007.

Sheila Weinmann1, Andrew E Williams2, Aruna Kamineni3, Diana S M Buist3, Erin E Masterson1, Natasha K Stout4, Azadeh Stark5, Tyler R Ross3, Christopher L Owens6, Terry S Field6, Chyke A Doubeni7.   

Abstract

BACKGROUND: Cervical cancer screening and follow-up guidelines have changed considerably in recent years, but to the authors' knowledge few published reports exist to estimate the impact of these changes in community-based settings. The authors examined the patterns and results of cervical cancer testing and follow-up over a decade in 4 geographically diverse US health care systems to inform the future evaluation of changes resulting from increased uptake of the human papillomavirus (HPV) vaccination.
METHODS: The authors studied women aged 21 to 65 years who were members of one of these health systems at any time between 1998 and 2007. Data were collected and standardized across sites, based on receipt of Papanicolaou (Pap) and HPV tests, HPV vaccination, cervical biopsies, and treatment of cervical dysplasia. Annual rates (per 1000 person-years) of Pap testing, HPV testing, and cervical biopsy and treatment procedures were calculated. Screening intervals and trends in the results of screening Pap tests and cervical biopsies also were examined.
RESULTS: Pap testing rates decreased (from 483 per 1000 person-years in 2000 to 412 per 1000 person-years in 2007) and HPV testing rates increased over the study period. Screening frequency varied across health care systems, and many women continued to receive annual testing. All 4 sites moved to less frequent screening over the study period without marked changes in the overall use of cervical biopsy or treatment.
CONCLUSIONS: Despite differences over time and across health plans in rates of cervical cancer testing and follow-up cervical procedures, the authors found no notable differences in Pap test results, diagnostic or treatment procedure rates, or pathological outcomes. This finding suggests that the longer screening intervals did not lead to more procedures or more cancer diagnoses.
© 2015 American Cancer Society.

Entities:  

Keywords:  Papanicolaou test; cervical cancer screening; cervical intraepithelial neoplasia; health care delivery systems; human papillomavirus testing; implementation science; screening guideline

Mesh:

Year:  2015        PMID: 25989253      PMCID: PMC4545722          DOI: 10.1002/cncr.29445

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Frequency of cervical smear abnormalities within 3 years of normal cytology.

Authors:  G F Sawaya; K Kerlikowske; N C Lee; G Gildengorin; A E Washington
Journal:  Obstet Gynecol       Date:  2000-08       Impact factor: 7.661

2.  Trade-offs in cervical cancer prevention: balancing benefits and risks.

Authors:  Natasha K Stout; Jeremy D Goldhaber-Fiebert; Jesse D Ortendahl; Sue J Goldie
Journal:  Arch Intern Med       Date:  2008-09-22

3.  Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes.

Authors:  E Lăără; N E Day; M Hakama
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

4.  Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS).

Authors:  Isam A Eltoum; Janie Roberson
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

5.  Costs associated with management of cervical human papillomavirus-related conditions.

Authors:  Denise Kruzikas; Jennifer S Smith; Carolyn Harley; Paul Buzinec
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-10       Impact factor: 4.254

6.  Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study.

Authors:  Björn Strander; Agneta Andersson-Ellström; Ian Milsom; Thomas Rådberg; Walter Ryd
Journal:  Cancer       Date:  2007-10-25       Impact factor: 6.860

7.  2006 consensus guidelines for the management of women with abnormal cervical screening tests.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  J Low Genit Tract Dis       Date:  2007-10       Impact factor: 1.925

Review 8.  Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

Authors:  Thomas C Wright; Mark Schiffman; Diane Solomon; J Thomas Cox; Francisco Garcia; Sue Goldie; Kenneth Hatch; Kenneth L Noller; Nancy Roach; Carolyn Runowicz; Debbie Saslow
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661

9.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Authors:  Mark E Sherman; Attila T Lorincz; David R Scott; Sholom Wacholder; Philip E Castle; Andrew G Glass; Iwona Mielzynska-Lohnas; Brenda B Rush; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

10.  Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation.

Authors:  L Gustafsson; H O Adami
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  8 in total

1.  Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.

Authors:  Michelle I Silver; Anne F Rositch; Darcy F Phelan-Emrick; Patti E Gravitt
Journal:  Cancer Causes Control       Date:  2017-11-09       Impact factor: 2.506

2.  Harms of cervical cancer screening in the United States and the Netherlands.

Authors:  Dik Habbema; Sheila Weinmann; Marc Arbyn; Aruna Kamineni; Andrew E Williams; Inge M C M de Kok; Folkert van Kemenade; Terry S Field; Joost van Rosmalen; Martin L Brown
Journal:  Int J Cancer       Date:  2017-03-01       Impact factor: 7.396

3.  De-implementation of cervical cancer screening before age 21.

Authors:  Michelle I Silver; Melissa L Anderson; Elisabeth F Beaber; Jennifer S Haas; Sarah Kobrin; Gaia Pocobelli; Celette Sugg Skinner; Jasmin A Tiro; Aruna Kamineni
Journal:  Prev Med       Date:  2021-09-29       Impact factor: 4.018

4.  Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence.

Authors:  Daniel X Yang; Pamela R Soulos; Brigette Davis; Cary P Gross; James B Yu
Journal:  Am J Clin Oncol       Date:  2018-03       Impact factor: 2.339

5.  Cervical cancer screening among women ≥70 years of age in the United States-A referral problem or patient choice.

Authors:  Fangjian Guo; Jacqueline M Hirth; Abbey B Berenson
Journal:  Prev Med       Date:  2015-10-21       Impact factor: 4.018

6.  Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System.

Authors:  Sandi L Pruitt; Claudia L Werner; Eric K Borton; Joanne M Sanders; Bijal A Balasubramanian; Arti Barnes; Andrea C Betts; Celette Sugg Skinner; Jasmin A Tiro
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-05       Impact factor: 4.254

7.  Identification of lncRNAs by microarray analysis reveals the potential role of lncRNAs in cervical cancer pathogenesis.

Authors:  Jiaming Huang; Tianyu Liu; Chunliang Shang; Yunhe Zhao; Wei Wang; Yanchun Liang; Luyan Guo; Shuzhong Yao
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

8.  Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women.

Authors:  Adana A M Llanos; Jennifer Tsui; David Rotter; Lindsey Toler; Antoinette M Stroup
Journal:  BMC Womens Health       Date:  2018-10-03       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.